Generex Oral-lyn™ — Competitive Intelligence Brief

Generex Oral-lyn™ (Generex Oral-lyn™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (oral formulation). Area: Diabetes.

phase 3 Insulin (oral formulation) Insulin receptor Diabetes Small molecule

Target snapshot

Generex Oral-lyn™ (Generex Oral-lyn™) — Generex Biotechnology Corp.. Oral-lyn is an oral insulin formulation that delivers insulin through the buccal mucosa to lower blood glucose in diabetes patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Generex Oral-lyn™ TARGET	Generex Oral-lyn™	Generex Biotechnology Corp.	phase 3	Insulin (oral formulation)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (oral formulation) class)

1. Generex Biotechnology Corp. · 1 drug in this class